FindTrial
Sign In

intervention group:Xeligekimab Injection

2 trials

Sponsors

Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venerology, Shandong First Medical University & Shandong Academy of Medical Sciences, People‘s Hospital of Xinjiang Uygur Autonomous Region

Conditions

Diagnosed with chronic moderate to severe plaque psoriasis (psoriasis-involved body surface area (BSA) >= 3% and Psoriasis Area and Severity Index (PASI) score >= 3 at screening baseline)Mild to Moderate Psoriasis

Phase 4

Efficacy and Safety of Xeligekimab in Patients with Mild-to-Moderate Psoriasis: A Prospective, Multicenter, Single-Arm Clinical Study
RecruitingChiCTR2600123675
Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venerology, Shandong First Medical University & Shandong Academy of Medical SciencesMild to Moderate Psoriasis
Start: 2026-04-28Updated: 2026-05-04

Unknown Phase

Real-world study of treatment with Xeligekimab in patients with moderate to severe plaque psoriasis in Xinjiang region
RecruitingChiCTR2600124090
People‘s Hospital of Xinjiang Uygur Autonomous RegionDiagnosed with chronic moderate to severe plaque psoriasis (psoriasis-involved body surface area (BSA) >= 3% and Psoriasis Area and Severity Index (PASI) score >= 3 at screening baseline)
Start: 2026-05-07Updated: 2026-05-11